Evaluation of Salivary Alkaline Phosphatase and Glutathione Peroxidase Levels in Diabetic and Nondiabetic Participants With and Without Smoking Habits: A Case-Control Study.

Background: The majority of the current evidence suggests that tobacco smoking increases the risk of diabetes. Salivary alkaline phosphatase (ALP) and glutathione peroxidase (GSHPx) considered a biomarker to detect various oral diseases. Several studies suggest that smoking habits tend to alter ALP and GSHPx levels. However, at present, there is no much information about these enzymes in smokers with diabetes. Hence, the study aimed to evaluate the status of salivary ALP and GSHPx levels in diabetic and nondiabetic participants with and without smoking habits. Materials and Methods: This case-control study was approved by the Institutional Ethical Committee. A total of 60 male participants between the age group 35-50 years were recruited. Informed consent was obtained from participants. Participants were categorized into four groups: Group I - Smokers with diabetes (n = 15), Group II - Smokers without diabetes (n = 15), Group III - Nonsmoker with diabetes (n = 15), and Group IV - Nonsmoker without diabetes (n = 15). Salivary ALP levels and GSHPx activity were measured by colorimetric assay. Data were compared between groups using the one-way analysis of variance, followed by a Bonferroni post-hoc test. Results: Nonsmoker diabetic participants demonstrated significantly higher ALP levels as compared to other groups (P < 0.05). We observed significantly lower levels of ALP in smokers with diabetes (P < 0.05). We observed a significant decrease in GSHPx activity in smokers with diabetes compared to all other groups (P < 0.05). Conclusions: Salivary ALP can be used as a clinical biomarker to be correlated for evaluating diabetes. GSHPx activity can be used to understand the response of supplementation therapy in smokers with diabetes.

A randomized triple-blind clinical trial to compare the effectiveness of topical triamcinolone acetonate (0.1%), clobetasol propionate (0.05%), and tacrolimus orabase (0.03%) in the management of oral lichen planus.

BACKGROUND: Oral lichen planus (OLP) is believed to result from an abnormal T-cell mediated immune response. The most useful agent in the treatment is corticosteroids. The present study will be aimed at evaluation of therapeutic efficiency of two corticosteroids triamcinolone acetonate (0.1%) and clobetasol propionate with tacrolimus orabase (0.03%), an immunomodulator in the management of OLP. AIM: To compare the effectiveness of topical triamcinolone acetonate (0.1%), clobetasol propionate (0.05%), and tacrolimus orabase (0.03%) in the management of OLP and also to compare which has less recurrence. STUDY DESIGN: The study comprises 30 patients, all were diagnosed with OLP clinically and histopathologically. They are randomly divided into three groups: Group A - triamcinolone acetonate (0.1%), Group B - clobetasol propionate (0.05%), and Group C - tacrolimus (0.03%). A formal informed consent was obtained from all of them who participated in the study. RESULTS AND CONCLUSION: Subjects in the Group A (triamcinolone 0.1%) and Group B (clobetasol 0.05%) show a significant reduction in lesion size than that of Group C (tacrolimus 0.03%). Group B (clobetasol 0.05%) shows a better significant reduction in lesion size than that of Group A (triamcinolone 0.1%). The overall treatment response was significant better in the Group B (clobetasol 0.05%). No recurrence was observed in any of the three groups at the end of 3 months. It is concluded that clobetasol propionate 0.05% ointment has higher efficacy when compared to triamcinolone acetonide 0.1% ointment and tacrolimus ointment 0.03% in the management of OLP. It was also inferred that triamcinolone 0.1% has better effects than tacrolimus 0.03%.